Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | GPR3 | P46089 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | PPARG | P37231 | 1/20 | 0.34 |
| ▸ | PPARA | Q07869 | 1/20 | 0.34 |
| ▸ | SLC22A2 | O15244 | 1/20 | 0.34 |
| ▸ | SLC22A3 | O75751 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.33 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30510259 | 1.00 | CYP1A2 (0.38) | CYP1A2TSHRGPR3KMT2APOLB | |
| SCHEMBL4599750 | 1.00 | CYP1A2 (0.38) | CYP1A2TSHRGPR3KMT2APOLB | |
| SCHEMBL1405873 | 1.00 | CYP1A2 (0.38) | CYP1A2TSHRGPR3KMT2APOLB | |
| SCHEMBL25177898 | 0.90 | CYP1A2 (0.37) | CYP1A2TSHRGPR3KMT2APOLB | |
| SCHEMBL8812896 | 0.88 | CYP1A2 (0.38) | CYP1A2TSHRGPR3KMT2APOLB | |
| SCHEMBL30510335 | 0.88 | CYP1A2 (0.38) | CYP1A2TSHRGPR3KMT2APOLB | |
| SCHEMBL5497625 | 0.88 | CYP1A2 (0.47) | CYP1A2TSHRGPR3KMT2APOLB | |
| SCHEMBL418100 | 0.88 | CYP1A2 (0.38) | CYP1A2TSHRGPR3KMT2APOLB | |
| SCHEMBL1000116 | 0.87 | BCHE (0.37) | CYP1A2TSHRKMT2APOLBMAPT | |
| SCHEMBL1000114 | 0.87 | BCHE (0.37) | CYP1A2TSHRKMT2APOLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4512818-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | Chugai Seiyaku Kabushiki Kaisha (JP) | 2025-02-26 | — | — | EP | disclosed |
| EP-4371982-A2 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX Pharmaceuticals, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| US-20240158446-A1 | CYCLIC COMPOUND HAVING SELECTIVE INHIBITORY ACTION ON KRAS OVER HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-16 | — | — | US | disclosed |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-05-09 | — | — | US | disclosed |
| EP-4316503-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-02-07 | — | — | EP | disclosed |
| EP-4309741-A1 | CYCLIC COMPOUND HAVING INHIBITORY EFFECT SELECTIVE FOR KRAS BUT NOT FOR HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2024-01-24 | — | — | EP | disclosed |
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2023-05-18 | — | — | US | disclosed |
| US-20230133667-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | RQX PHARMACEUTICALS INC (US) | 2023-05-04 | — | — | US | disclosed |
| WO-2021236475-A1 | COMPOUNDS THAT INHIBIT ASPARAGINE SYNTHETASE AND THEIR METHODS OF USE | ASINEX CORPORATION (US) | 2021-11-25 | — | — | WO | disclosed |
| US-20210198316-A9 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | CHARLES RIVER DISCOVERY RESEARCH SERVICES UK LIMITED (GB) | 2021-07-01 | — | — | US | disclosed |
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | MIGENIX INC. (CA) | 2008-07-17 | — | — | US | disclosed |
| WO-2008080223-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | MIGENIX INC. (CA) | 2008-07-10 | — | — | WO | disclosed |
| EP-1910279-A2 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2008-04-16 | — | — | EP | disclosed |
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-25 | — | — | US | disclosed |
| WO-2007002639-A2 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | MIGENIX INC. (CA) | 2007-01-04 | — | — | WO | disclosed |
| US-7132536-B2 | Triaza- and tetraaza-anthracenedione derivatives, their preparation and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2006-11-07 | — | — | US | disclosed |
| EP-1641795-A1 | TRIAZA- AND TETRAAZA-ANTHRACENEDIONE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS | Sanofi-Aventis Deutschland GmbH (DE) | 2006-04-05 | — | — | EP | disclosed |
| US-20040248900-A1 | Triaza- and tetraaza-anthracenedione derivatives, their preparation and their use as pharmaceuticals | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-12-09 | — | — | US | disclosed |
| WO-2004094425-A1 | Triaza- and tetraaza-anthracenedione derivatives, their preparation and their use as pharmaceuticals | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2004-11-04 | — | — | WO | disclosed |
| EP-1471066-A1 | Triaza- and tetraaza-anthracenedione derivates, their preparation and their use as pharmaceuticals | Aventis Pharma Deutschland GmbH (DE) | 2004-10-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230151060-A1 | CYCLIC PEPTIDE COMPOUND HAVING KRAS INHIBITORY ACTION | KRAS, NRAS, HRAS | CYP1A2 4845/4885TSHR 3295/4885GPR3 2165/4885 |
| US-20070021434-A1 | NON-NUCLEOSIDE ANTI-HEPACIVIRUS AGENTS AND USES THEREOF | HAVCR2, ADAR, NSUN2 | CYP1A2 3094/4885TSHR 2471/4885GPR3 3046/4885 |
| US-20240158446-A1 | CYCLIC COMPOUND HAVING SELECTIVE INHIBITORY ACTION ON KRAS OVER HRAS AND NRAS | KRAS, HRAS, NRAS | CYP1A2 4842/4885TSHR 3652/4885GPR3 1761/4885 |
| US-20040248900-A1 | Triaza- and tetraaza-anthracenedione derivatives, their preparation and their use as pharmaceuticals | CYP19A1, TBXAS1, CYP11B1 | CYP1A2 14/4885TSHR 1134/4885GPR3 3368/4885 |
| US-20080171783-A1 | COMPOSITIONS AND METHODS FOR TREATING HYPERPROLIFERATIVE DISEASE | POLQ, POLI, POLH | CYP1A2 4344/4885TSHR 4481/4885GPR3 4690/4885 |
| US-20240148821-A1 | PHARMACEUTICAL USE OF CYCLIC PEPTIDE COMPOUND | VIP, IAPP, KRAS | CYP1A2 4648/4885TSHR 1619/4885GPR3 712/4885 |
| US-20210198316-A9 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | MRPL21, PEPD, CTSC | CYP1A2 4095/4885TSHR 4174/4885GPR3 4652/4885 |
| US-20230133667-A1 | MACROCYCLIC BROAD SPECTRUM ANTIBIOTICS | MRPL21, PEPD, CTSC | CYP1A2 4095/4885TSHR 4174/4885GPR3 4652/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.